Experimental Approach
We administrated monotherapy or combination therapy of pirfenidone and
nintedanib with low and high doses in silicosis mouse models established
after 6 weeks and then evaluated lung function, inflammatory responses,
and fibrotic status. Moreover, we employed transcriptomic and
metabolomic analyses to unravel the mechanisms underlying different
therapeutic strategies.